{
    "risk_classification": "biopharmaceutical",
    "confidence_score": 0.85,
    "social_media_risk": 0.15,
    "reason": "The recent share price movement of Mustang Bio, Inc. (NASDAQ: MBIO) is likely influenced by the announcement of the FDA granting Orphan Drug Designation for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of astrocytomas and glioblastoma. This designation provides incentives such as tax credits and market exclusivity, which are significant for the company's future prospects. The news is substantial and directly related to the company's core business, suggesting a high confidence that this is the primary driver of the recent share price activity."
}